Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2015

View Archived Issues

biOasis Technologies and Brigham and Women's Hospital form neuro-oncology R&D agreement

Lilly divulges several analyses of phase III solanezumab trial data

Allogeneic mesenchymal precursor cells show promising results for the treatment of type 2 diabetes

ASK-1 inhibition protects mice from thrombosis

Lpath receives FDA clearance to start phase I trial of Lpathomab

Lupin to acquire Gavis

Researchers publish preclinical data that led to advancement of antimalarial agent DSM-265

Bausch + Lomb submits Vesneo NDA

Zalviso recommended for approval in Europe

EMA committee grants accelerated assessment to ixazomib for relapsed/refractory multiple myeloma

FDA approves Odomzo for locally advanced BCC

Biohaven files IND for BHV-0223 for treatment-resistant affective disorders

Algomedix presents TRPA1 antagonists

Bristol-Myers Squibb patents ROR-gamma modulators

Blend Therapeutics divulges platinum complexes for cancer

Jiangsu Hansoh Pharmaceutical Group introduces NS5B inhibitors

Rhizen Pharmaceuticals patents glutaminase inhibitors

FDA approves Technivie for genotype 4 chronic HCV infection

Genentech to advance crenezumab into phase III for prodromal to mild Alzheimer's disease

EMA committee recommends approval of Fexeric

FDA approves Praluent to treat high LDL cholesterol

EMA committee recommends approval of Intuniv for ADHD in children and adolescents

FDA approves Daklinza for genotype 3 chronic HCV infection

Genzyme to acquire vandetanib from AstraZeneca

EMA Committee hands down positive opinion for Revolade in severe aplastic anemia

FDA approves Kyprolis in combination use for relapsed multiple myeloma

Omeros's OMS-721 receives fast track designation for aHUS

European recommendation, U.S. priority review for Tafinlar and Mekinist combination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...